

POSITRON CORP
Form 10-Q
November 14, 2011

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

For the quarterly period ended September 30, 2011

Commission file number 000-29449

POSITRON CORPORATION

(Exact Name of Registrant as specified in its charter)

Texas
(State or Other Jurisdiction of Incorporation or
Organization)

76-0083622
(IRS Employer Identification No.)

9715 Kincaid Boulevard, Suite 1000, Fishers, Indiana
(Address of Principal Executive Offices)

46038
(Zip Code)

Registrant's Telephone Number, Including Area Code: (317) 576-0183

Indicate by check mark whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes No

Indicate by check mark whether the registrant is a larger accelerated filer, an accelerated filer, a non-accelerated or a smaller reporting company filer. See the definition of "large accelerated filer, accelerated filer and smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one)

Large accelerated filer
Non-accelerated filer

Accelerated filer
Smaller reporting company

Edgar Filing: POSITRON CORP - Form 10-Q

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes No

The numbers of shares outstanding of each of the issuer's classes of common equity, as of November 11, 2011, are as follows:

Class of Securities	Shares Outstanding
Common Stock, \$0.01 par value	797,827,497

POSITRON CORPORATION

TABLE OF CONTENTS

INDEX	Page
PART I - FINANCIAL INFORMATION	
ITEM 1 – Financial Statements - Unaudited	3
Consolidated Balance Sheet at September 30, 2011 (unaudited) and December 31, 2010	3
Consolidated Statement of Operations for the three and nine months ended September 30, 2011 and 2010 (unaudited)	4
Consolidated Statement of Cash Flows for the nine months ended September 30, 2011 and 2010 (unaudited)	5
Notes to Consolidated Financial Statements (unaudited)	6
ITEM 2- Management’s Discussion and Analysis of Financial Condition and Results of Operations	14
ITEM 3 - Quantitative and Qualitative Disclosures About Market Risk	18
ITEM 4 - Controls and Procedures	18
PART II- OTHER INFORMATION	
ITEM 1 – Legal Proceedings	20
ITEM 2 – Unregistered Sales of Equity Securities and Use of Proceeds	20
ITEM 3 – Defaults Upon Senior Securities	20
ITEM 4 – Removed and Reserved	20
ITEM 5 – Other information	20
ITEM 6– Exhibits	21
SIGNATURES	21
EXHIBITS	

PART 1 – FINANCIAL INFORMATION

ITEM 1. Financial Statements

POSITRON CORPORATION AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(In thousands, except share data)
(Unaudited)

	September 30, 2011 (Unaudited)	December 31, 2010
ASSETS		
Current assets:		
Cash and cash equivalents	\$ 194	\$ 1,141
Accounts receivable	1,215	514
Inventories	798	622
Prepaid expenses	71	28
Deposits – Attrius® PET systems	560	2,484
Total current assets	2,838	4,789
Property and equipment, net	202	251
Deferred rent	85	111
Other assets	30	22
Total assets	\$ 3,155	\$ 5,173
LIABILITIES AND STOCKHOLDERS' DEFICIT		
Current liabilities:		
Accounts payable and accrued liabilities	\$ 1,434	\$ 803
Customer deposits	1,952	4,203
Unearned revenue	297	253
Total current liabilities	3,683	5,259
Convertible debenture, net	173	—
Embedded conversion derivative liabilities	1,267	—
Total liabilities	5,123	5,259
Stockholders' deficit:		
Series A Preferred Stock: \$1.00 par value; 8% cumulative, convertible, redeemable; 5,450,000 shares authorized; 457,599 shares issued and outstanding.	457	457
Series B Preferred Stock: \$1.00 par value; convertible, redeemable; 9,000,000 shares authorized; 7,615,186 and 6,668,444 shares issued and outstanding	7,307	6,361
Series G Preferred Stock: \$1.00 par value; convertible, redeemable; 3,000,000 shares authorized; 19,200 and 19,200 shares issued and outstanding	19	19
Series S Preferred Stock: \$1.00 par value; convertible, redeemable; 100,000 shares authorized; 100,000 shares issued and outstanding	100	100
	7,662	7,511

Edgar Filing: POSITRON CORP - Form 10-Q

Common stock: \$0.01 par value; 800,000,000 shares authorized; 797,827,497 and 782,727,497 shares outstanding.		
Additional paid-in capital	89,970	88,126
Other comprehensive income	(143)	(143)
Receivable for exercise of warrants	(50)	(250)
Accumulated deficit	(107,275)	(102,252)
Treasury Stock: 60,156 shares at cost	(15)	(15)
Total stockholders' deficit	(1,968)	(86)
Total liabilities and stockholders' deficit	\$ 3,155	\$ 5,173

See accompanying notes to consolidated financial statements

POSITRON CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share data)
(Unaudited)

	Three Months Ended		Nine Months Ended	
	September 30, 2011	September 30, 2010	September 30, 2011	September 30, 2010
Revenues:	\$ 482	\$ 1,013	\$ 6,374	\$ 2,414
Costs of revenues:	501	1,126	6,033	2,141
Gross profit (loss)	(19)	(113)	341	273
Operating expenses:				
Research and development	401	417	1,062	881
Selling and marketing	221	343	888	779
General and administrative	459	1,761	1,791	11,493
Total operating expenses	1,081	2,521	3,741	13,153
Loss from operations	(1,100)	(2,634)	(3,400)	(12,880)
Other income (expense)				
Interest expense	(123)	—	(900)	(43)
Derivative losses	(230)	2,104	(723)	2,104
Other income	—	824	—	1,455
Total other income (expense)	(353)	2,928	(1,623)	3,516
Income (loss) before income taxes	(1,453)	294	(5,023)	(9,364)
Income taxes	—	—	—	—
Net income (loss)	\$ (1,453)	\$ 294	\$ (5,023)	\$ (9,364)
Other comprehensive income				
Foreign currency translation loss	—	(29)	—	(17)
Comprehensive income (loss)	\$ (1,453)	\$ 265	\$ (5,023)	\$ (9,381)
Basic and diluted income (loss) per common share	\$ (0.00)	\$ 0.00	\$ (0.01)	\$ (0.02)
Weighted average number of basic and diluted common shares outstanding	797,751	755,595	790,653	582,766

See accompanying notes to financial statements

POSITRON CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
(Unaudited)

	Nine Months Ended	
	September 30, 2011	September 30, 2010
Cash flows from operating activities:		
Net loss	\$(5,023)	\$(9,364)
Adjustment to reconcile net loss to net cash used in operating activities		
Depreciation and amortization	57	24
Derivative losses (gains)	723	(2,104)
Common stock issued for services	386	6,284
Preferred stock issued for services	54	441
Deferred rent	26	(119)
Accretion of interest	873	—
Stock based compensation	—	2,500
Preferred stock issued for post-acquisition contingent payment	—	400
Forgiveness of interest	—	(367)
Settlement of accounts payable	—	(986)
Forgiveness of accrued compensation	—	(103)
Bad debt expense	—	34
Inventory reserve	—	239
Changes in operating assets and liabilities:		
Accounts receivable	(701)	(230)
Inventories	(176)	(221)
Prepaid expenses	(43)	(65)
Other assets	1,916	(13)
Accounts payable and accrued liabilities	631	(748)
Customer deposits	(2,251)	1,592
Deposits	—	(1,957)
Unearned revenue	44	88
Net cash used in operating activities	(3,484)	(4,675)
Cash flows from investing activities:		
Purchase of property and equipment	(8)	(196)
Net cash used in investing activities	(8)	(196)
Cash flows from financing activities:		
Advance from related party	—	(575)
Proceeds from convertible debt	1,700	—
Payment of convertible note	—	(1,000)
Proceeds from common stock	—	5,131
Deposits for unissued securities	—	2,016
Repayments of advances to affiliated entities	—	39

Edgar Filing: POSITRON CORP - Form 10-Q

Proceeds from exercise of warrants	845	—
Net cash provided by financing activities	2,545	5,611
Effect of exchange rate changes on cash and cash equivalents	—	(17)
Net increase (decrease) in cash and cash equivalents	(947)	723
Cash and cash equivalents, beginning of period	1,141	165
Cash and cash equivalents, end of period	\$194	\$888
Supplemental cash flow information:		
Interest paid	\$—	\$—
Income taxes paid	—	—
Non-cash disclosures		
Conversion of Series B Preferred Stock to common stock	\$20	\$1,324
Conversion of Series G Preferred Stock to common stock	\$—	\$33
Payment of convertible notes payable and accrued interest with common stock	\$—	\$680
Allocation of Convertible Debentures to warrants and embedded conversion derivative liability	\$1,700	\$—
Conversion of Convertible Debentures to Series B Preferred stock	\$700	\$—
Conversion of embedded conversion derivative liability to paid in capital	\$883	\$—

See accompanying notes to consolidated financial statements

POSITRON CORPORATION AND SUBSIDIARIES
SELECTED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

1. Basis of Presentation

The accompanying unaudited interim financial statements have been prepared in accordance with generally accepted accounting principles and the rules of the U.S. Securities and Exchange Commission, and should be read in conjunction with the audited financial statements and notes thereto contained in the Annual Report on Form 10-K for Positron Corporation (the “Registrant” or the “Company”) for the year ended December 31, 2010. In the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of financial position, results of operations and cash flows for the interim periods presented have been reflected herein. The results of operations for interim periods are not necessarily indicative of the results to be expected for the full year. Notes to the financial statements which would substantially duplicate the disclosures contained in the audited financial statements for the most recent fiscal year ended December 31, 2010, as reported in the Form 10-K, have been omitted.

In preparing the interim unaudited consolidated financial statements, management was required to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosures at the financial reporting date and throughout the periods being reported upon. Certain of the estimates result from judgments that can be subjective and complex and consequently actual results may differ from these estimates.

All significant intercompany balances and transactions have been eliminated.

2. Accounting Policies

For a summary of significant accounting policies (which have not changed from December 31, 2010), see the Company’s Annual Report on Form 10-K for the year ended December 31, 2010.

Use of estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported amount of revenues and expenses during the reporting period. Actual results could differ from these estimates.

Debt discount

Costs incurred with parties who are providing long-term financing, which generally include the value of warrants or the fair value of an embedded derivative conversion feature are reflected as a debt discount and are amortized over the life of the related debt. The debt discount attributable to the warrants issued with convertible debentures during the nine months ended September 30, 2011 was \$273,000. The debt discount attributable to the embedded conversion derivative liability was \$1,427,000 during the nine months ended September 30, 2011.

Fair value of financial instruments

The carrying value of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities and unearned revenue, approximate their fair values because of the short-term nature of these instruments. Management

believes the Company is not exposed to significant interest or credit risks arising from these financial instruments.

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. The Company utilizes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable.

Level 1 — Quoted prices in active markets for identical assets or liabilities. These are typically obtained from real-time quotes for transactions in active exchange markets involving identical assets.

Level 2 — Quoted prices for similar assets and liabilities in active markets; quoted prices included for identical or similar assets and liabilities that are not active; and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets. These are typically obtained from readily-available pricing sources for comparable instruments.

Level 3 — Unobservable inputs, where there is little or no market activity for the asset or liability. These inputs reflect the reporting entity's own beliefs about the assumptions that market participants would use in pricing the asset or liability, based on the best information available in the circumstances.

The following table presents the embedded conversion derivative liabilities, the Company's only financial liabilities measured and recorded at fair value on the Company's consolidated balance sheets on a recurring basis and their level within the fair value hierarchy as of September 30, 2011(in thousands):

	September 30,			
	2011	Level 1	Level 2	Level 3
Embedded conversion derivative liability	\$ 1,267	\$ -	\$ -	\$ 1,267

The following table reconciles, for the nine months ended September 30, 2011, the beginning and ending balances for financial instruments that are recognized at fair value in the consolidated financial statements (in thousands):

Balance of embedded conversion derivative liability as of December 31, 2010	\$-
Fair value of embedded conversion derivative liabilities at issuance	1,427
Reductions in fair value due to conversion of Convertible Debentures to Series B Preferred Stock	(883)
Loss on fair value adjustments to embedded conversion derivative liabilities	723
Balance of embedded conversion derivative liabilities at September 30, 2011	\$1,267

The fair value of the conversion features are calculated at the time of issuance and the Company records a derivative liability for the calculated value using a Black-Scholes option-pricing model. Changes in the fair value of the derivative liability are recorded in other income (expense) in the consolidated statements of operations. Upon conversion of the convertible debt to stock, the Company reclassifies the related embedded conversion derivative liability to paid in capital. Since the fair value of the embedded conversion derivative liability exceeded the carrying value of the convertible debentures on the issuance date, the convertible debentures were recorded at a full discount. The Company recognizes expense for accretion of the convertible debentures discount over the term of the notes. The Company has considered the provisions of ASC 480, Distinguishing Liabilities from Equity, as the conversion feature embedded in each debenture could result in the note principal being converted to a variable number of the Company's common shares.

Revenue Recognition

Prior to July 1, 2010, revenues from system contracts and other nuclear imaging devices were recognized when all significant costs have been incurred and the system has been shipped to the customer and in cases, when the Company is responsible for installation, after installation is complete. Revenues from maintenance contracts were recognized over the term of the contract. Service revenues were recognized upon performance of the services.

The delivered items, specifically: a) the medical machine, delivery and installation, and b) the one year warranty/service agreement, are considered separate units of accounting. Both have value to the customer on a standalone basis, each have objective and reliable evidence of their fair values and the performance of each item is considered probable and in control of the Company to perform. Additionally, performance and delivery of the delivered items are the responsibility of the Company and would be liable for any type of return.

Selling prices of the deliverable items are established based on list prices of similar items, including delivery, installation and maintenance contracts (for years subsequent to the one year warranty/service period). We utilize competitive information to align price points for each specific unit. There is a detailed proposal for each customer, breaking down each deliverable as well as the price for future annual service agreements. The general timing of

delivery and performance of each specific unit differs depending on the customer, but generally delivery, installation and acceptance occur within 120-150 days of the signed contract and the warranty/service covers one year after acceptance and final payment. Cancellation of the agreements are allowed with full or partial refund within specified time periods prior to shipment. Product returns based on improper shipment or apparent damage may be claimed in writing within 14 days of receipt of the machine and must be accepted by the Company. Revenue is not recognized until unit is properly tested and written acceptance is provided by the buyer.

Revenue from sales of Attriuss® PET systems is recognized on a gross basis because the sale of the Attriuss® product meets the various requirements identified in Topic 605-45-45, including:

- 1) The Company is the primary obligor in the arrangement. All sales agreements are between the Company and the buyer and the Company is responsible for delivery and performance of the machines.
- 2) The Company has full responsibility for any returned products from customers and has general inventory risk.
- 3) The Company has complete authority over establishing the price of the individual units of our sales agreements and has full credit risk with regards to collection.
- 4) All machines are installed and serviced by the Company.
- 5) All machines acquired from its joint venture partner are sold FOB shipping point.

Recent Accounting Pronouncements

Recently issued or adopted accounting pronouncements are not expected to, or did not have, a material impact on our financial position, results of operations or cash flows.

Reclassifications

Certain items in the financial statements for 2010 have been reclassified to conform with the current year presentation. Such reclassification had no effect on net income.

3. Going Concern

Since inception, the Company has expended substantial resources on research and development and sustained losses. Due to the limited number of systems sold or placed into service each year, revenues have fluctuated significantly from year to year and have not been sufficient to be operationally profitable. The Company had an accumulated deficit of \$107,275,000 and a stockholders' deficit of \$1,968,000 at September 30, 2011. The Company will need to increase sales and apply the research and development advancements to achieve profitability in the future. The Company expects to experience a significant increase in sales of the Attriuss® Positron Emission Tomography ("PET") system and additional service agreements; it also expects recurring revenue from the sale of radiopharmaceuticals through PosiRx™, its automated radiopharmaceutical system and sales of radiopharmaceuticals manufactured at its Crown Point facility. The Company expects that these developments will have a positive impact on revenue and net margins.

The Company had cash and cash equivalents of \$194,000 at September 30, 2011. At the same date, the Company had accounts payable and accrued liabilities of \$1,434,000 at September 30, 2011. Working capital requirements for the upcoming year may reach beyond our current cash balances. As the Company executes its plans for expansion, it may increase sales and services to meet business operations however it may also continue to raise funds as required through equity and debt financing to sustain business operations if necessary. The Company expects to achieve sufficient revenues or raise sufficient funds to sustain business operations; however, no assurance can be given.

4. Deposits - Attriuss® PET systems

At September 30, 2011, the Company had \$560,000 in deposits paid to our joint venture partner, Neusoft Positron Medical Systems Co., Ltd., ("Neusoft") for Attriuss® PET systems for which the Company has sales contracts on three Attriuss® PET systems.

5. Inventories

Inventories consisted of the following (in thousands) as of:

	September 30, 2011	December 31, 2010
Finished systems	\$ 150	\$ 120
Raw materials and service parts	383	379
Work in progress	632	490
	1,165	989
Less: Reserve for obsolete inventory	(367)	(367)
	\$ 798	\$ 622

Inventories are stated at the lower of cost or market. Cost is determined using the first-in, first-out (FIFO) method of inventory valuation. The Company evaluated the reserve as of September 30, 2011 and December 31, 2010.

6. Property and equipment

Property and equipment consisted of the following (in thousands) as of:

	September 30, 2011	December 31, 2010
Furniture and fixtures	\$ 27	\$ 21
Leasehold improvements	19	19
Computer equipment	57	55
Machinery and equipment	214	214
	317	309
Less: Accumulated depreciation	(115)	(58)
	\$ 202	\$ 251

7. Customer Deposits

Customer deposits represent amounts paid to the Company by customers for devices in advance of manufacturing completion and/or shipment of the device to the customer. Deposit amounts may vary depending on the contract. Included in customer deposits at September 30, 2011 were deposits of approximately \$669,000 from a customer that had placed an order in 2007 for five Nuclear Pharm-Assist™ systems. As of the date of this report, there can be no assurance that this customer will fulfill its order for these devices.

Also, included in customer deposits at September 30, 2011 are \$1,283,000 deposits on three Attrius® PET systems sale orders and two used machines.

8. Income (Loss) Per Share

Basic loss per common share is based on the weighted average number of common shares outstanding in each period and earnings adjusted for preferred stock dividend requirements. Diluted earnings per common share assumes that any dilutive convertible preferred shares outstanding at the beginning of each period were converted at those dates, with related interest, preferred stock dividend requirements and outstanding common shares adjusted accordingly. It also assumes that outstanding common shares were increased by shares issuable upon exercise of those stock options and warrants for which market price exceeds exercise price, less shares which could have been purchased by the Company with related proceeds. The convertible preferred stock and outstanding stock options and warrants were not included in the computation of diluted earnings per common share for the three and nine months ended September 30, 2011 and 2010, respectively since it would have resulted in an antidilutive effect.

The following table sets forth the computation of basic and diluted loss per share (In thousands, except per share data).

Three Months Ended		Nine Months Ended	
September 30, 2011	September 30, 2010	September 30, 2011	September 30, 2010
(In thousands, except per share data)			

Numerator

Edgar Filing: POSITRON CORP - Form 10-Q

Basic and diluted income (loss)	\$ (1,453)	\$ 294	\$ (5,023)	\$ (9,364)
Denominator				
Basic and diluted earnings per share- weighted average shares outstanding	797,751	755,595	790,653	582,766
Basic and diluted income (loss) per common share	\$ (0.00)	\$ 0.00	\$ (0.01)	\$ (0.02)

Anti-dilutive securities (based on conversions to common shares) not included in net loss per share calculation:

	September 30, 2011	September 30, 2010
Convertible Series A Preferred Stock	457	457
Convertible Series B Preferred Stock	761,519	608,859
Convertible Series G Preferred Stock	1,920	2,920
Convertible Series S Preferred Stock	1,000,000	1,000,000
Stock Warrants	169,583	238,563
Convertible debt	102,643	-
Common Stock Options	-	26,450
Preferred Stock Options	250,000	250,000

9. Convertible Debentures

On April 26, 2011, the Company issued \$1,300,000 of convertible debentures (“Convertible Debentures”) to certain investors (“Investors”). Interest accrues at the rate of eight percent per annum and is payable quarterly in cash. The debentures mature on December 31, 2012. In addition, the Company issued 6,500,000 warrants (“Warrants”), which entitle the Investors to purchase shares of the Company’s common stock, par value \$0.01 per share, at an exercise price of \$0.03 per share and expiring on December 31, 2013. The Investors are entitled to convert the accrued interest and principal of the Convertible Debentures into common stock of the Company at a conversion price equal to 55% of the lowest daily volume weighted average price for the three trading days preceding conversion.

Initial Accounting

Under the initial accounting, the Company separated the Convertible Debentures instrument into component parts of the Convertible Debentures, the Warrants and the embedded conversion derivative liability. The Company estimated the fair value of each component as of the date of issuance and allocated net proceeds initially to the Warrants based on a relative fair value fair value of the Convertible Debentures and the Warrants and then allocated the remaining proceeds to the embedded conversion derivative liability. The fair value of the embedded conversion derivative liability exceeded the proceeds from the Convertible Debentures less the allocation of the proceeds to the Warrants, which resulted in a debt discount of \$1,300,000. The debt is accreted to interest expense over the life of the Convertible Debentures.

The following is a summary of the proceeds from the issuance of the Convertible Debentures and the initial accounting of the issuance (in thousands):

Proceeds from convertible debt issuance	\$1,300
Allocation of proceeds to warrants	(168)
Allocation of proceeds to embedded conversion derivative liability	(1,132)
Total	\$-

On August 17, 2011 and September 28, 2011, the Company issued \$200,000 and \$200,000, respectively of convertible debentures (“Convertible Debt”) to certain investors (“Debt Investors”). Interest accrues at the rate of eight percent per annum and is payable quarterly in cash. The debentures mature on December 31, 2012. In addition, the Company issued 8,500,000 warrants (“\$0.01 Warrants”), which entitle the Debt Investors to purchase shares of the Company’s common stock, par value \$0.01 per share, at an exercise price of \$0.01 per share and expiring on December 31, 2013. The Debt Investors are entitled to convert the accrued interest and principal of the Convertible Debentures

into common stock of the Company at a conversion price equal to 55% of the lowest daily volume weighted average price for the three trading days preceding conversion.

Initial Accounting

Under the initial accounting, the Company separated the Convertible Debentures instrument into component parts of the Convertible Debt, the \$0.01 Warrants and the embedded conversion derivative liability. The Company estimated the fair value of each component as of the date of issuance and allocated net proceeds initially to the \$0.01 Warrants based on a relative fair value fair value of the Convertible Debt and the \$0.01 Warrants and then allocated the remaining proceeds to the embedded conversion derivative liability. The fair value of the embedded conversion derivative liability exceeded the proceeds from the Convertible Debt less the allocation of the proceeds to the \$0.01 Warrants, which resulted in a debt discount of \$400,000. The debt is accreted to interest expense over the life of the Convertible Debt.

The following is a summary of the proceeds from the issuance of the Convertible Debt and the initial accounting of the issuance (in thousands):

Proceeds from convertible debt issuance	\$400
Allocation of proceeds to \$0.01 warrants	(105)
Allocation of proceeds to embedded conversion derivative liability	(295)
Total	\$-

Conversion of Convertible Debentures to Series B Shares

On May 26, 2011, the Investors converted \$700,000 of the Convertible Debentures to 424,242 Series B preferred shares. In connection with the conversion of these Convertible Debentures, the Company recognized interest expense of \$700,000.

Convertible debentures as of September 30, 2011

During the three months and nine months ended September 30, 2011, the Company recognized \$64,000 and \$173,000, respectively of interest expense on the Convertible Debentures still outstanding as of September 30, 2011(in thousands).

	September 30, 2011	December 31, 2010
Convertible debentures – face value	\$ 1,000	\$ —
Debt discount	(827)	—
Total convertible debentures, net	\$ 173	\$ —

10. Stockholders' Deficit

2011

On February 15, 2011, the Company issued 3,000 shares of Series B preferred stock to an unrelated party for consulting services. On the date of issuance, the common stock had a fair market value of \$0.04 per share. The Company recorded consulting fee expense of \$12,000 for the issuance of the shares.

On April 6, 2011, the Company issued 300,000 shares of common stock to an unrelated party for consulting services. On the date of issuance, the common stock had a fair market value of \$0.04 per share. The Company recorded consulting fee expense of \$12,000 for the issuance of the shares.

On May 27, 2011, the Company issued 12,300,000 shares of common stock to an unrelated party for consulting services. On the date of issuance, the common stock had a fair market value of \$0.029 per share. The Company recorded consulting fee expense of \$357,000 for the issuance of the shares.

On June 21, 2011, the Company issued 11,500 shares of Series Preferred B stock to two unrelated parties for consulting services. On the date of issuance, the common stock had a fair market value of \$0.03 per share. The Company recorded consulting fee expense of \$33,000 for the issuance of the shares.

During the nine months ended September 30, 2011, investors exercised warrants on preferred stock for which the Company received \$595,000 in cash proceeds and issued 130,000 shares of Series B preferred stock. In addition, the Company received \$250,000 in cash proceeds for warrants and issued 125,000 shares of Series B preferred stock, which were exercised at December 31, 2010, and recorded as receivable from warrants exercise at December 31, 2010.

On July 15, 2011, the Company issued 500,000 shares of common stock to an unrelated party for consulting services. On the date of issuance, the common stock had a fair market value of \$0.034 per share. The Company recorded consulting fee expense of \$17,000 for the issuance of the shares.

On August 2, 2011, the Company issued 3,000 shares of Series B stock to an unrelated party for consulting services. On the date of issuance, the common stock had a fair market value of \$0.03 per share. The Company recorded consulting fee expense of \$9,000 for the issuance of the shares.

2010

During the nine months ended September 30, 2010, the Company issued 191,141,674 shares of common stock to unrelated investors for cash in the amount of approximately \$5,131,000.

During the nine months ended September 30, 2010, investors converted 1,323,860 shares of Series B Preferred Stock into 132,386,000 shares of common stock. Investors also converted 33,191 shares of Series G Preferred stock into 3,319,100 shares of common stock.

During the nine months ended September 30, 2010, the Company issued 52,550,000 shares of common stock to unrelated parties for consulting services. On the dates of issuance the shares had an aggregate fair market value of \$6,284,000 for which the Company recorded consulting fee expense.

During the nine months ended September 30, 2010, the Company issued 291,777 shares of Series B Preferred Stock to unrelated parties for consulting services. Accordingly, the Company recorded consulting fee expense of \$441,000 related to the issuance of the shares.

On June 24, 2010, the Company issued 200,000 Series B Preferred shares to the former owners of Dose Shield pursuant to the terms of the purchase agreement ("Agreement") between Dose Shield and the Company dated June 5, 2008. On August 12, 2010, the Company issued an additional 200,000 Series B Preferred shares to the former owners of Dose Shield pursuant to the terms of the Agreement. Since all recorded goodwill related to the Dose Shield acquisition has been previously written off as an impairment charge, the Company recorded a charge of \$400,000 related to the issued Series B shares.

At September 30, 2010, the Company had deposits of \$2,016,000 from investors for equity securities that were not yet issued. The amount is recorded as a non-current liability at September 30, 2010.

11. Stock Options

For all of the Company's stock-based compensation plans, the fair value of each grant was estimated at the date of grant using the Black-Scholes option-pricing model. Black-Scholes utilizes assumptions related to volatility, the risk-free interest rate, the dividend yield (which is assumed to be zero, as the Company has not paid cash dividends to date and does not currently expect to pay cash dividends) and the expected term of the option. Expected volatilities utilized in the model are based mainly on the historical volatility of the Company's stock price over a period commensurate with the expected life of the share option as well as other factors. The risk-free interest rate is derived from the zero-coupon U.S. government issues with a remaining term equal to the expected life at the time of grant.

In January 2010 the Company granted certain employees options to purchase 2,500,000 shares of Series B Preferred stock at an exercise price of \$1.00 per share (the "Preferred Options".) The options vest immediately and have a term of four years. Accordingly, in January 2010 the Company recorded compensation expense of \$2,500,000 for the Preferred Option grants. Fair market value using the Black-Scholes option-pricing model was determined using the following assumptions:

Expected life (years)	4	
Risk free rate of return	2.5	%
Dividend yield	0	
Expected volatility	378	%

12. Related Party Transactions

During the nine months ended September 30, 2011, the Company recognized cost of revenues of approximately \$4,521,000 related to the purchase of Attrius® PET systems from Neusoft, the Company's joint venture. At September 30, 2011, the Company has recorded deposits totaling \$560,000 to Neusoft for three machines. At September 30, 2011, the Company also has a \$250,000 receivable from Neusoft for certain excess freight charges owed, and has \$218,000 payable to Neusoft for the purchase of an Attrius® PET system. The Company continues to pursue collection of the \$250,000 receivable from Neusoft and does not believe a bad debt reserve is needed for the receivable at this time as the Company believes the balance is fully collectible and contractually owed.

During the nine months ended September 30, 2010, the Company recognized cost of revenues of \$1,317,679 related to the purchase of Attrius® PET systems from Neusoft. During the nine months ended September 30, 2010, the Company paid \$200,000 of consulting fees to a related party.

13. Commitments

On July 7, 2011, the Company entered into an operating lease with a third party for space for warehousing and medical device assembly at a building in Fishers, Indiana. The Company will be required to make payments of \$5,083 each month from December 1, 2011 through November 13, 2013, and \$5,287 from December 1, 2013 through November 30, 2016.

14. Segment Disclosures

We have aggregated our operations into two reportable segments based upon product lines, manufacturing processes, marketing and management of our businesses: medical equipment and radiopharmaceuticals. Our business segments operate in the nuclear medicine industry. The Company's medical equipment segment is currently generating all revenues and the majority of all expenses as the radiopharmaceuticals segment is still in the development phase.

We evaluate a segment's performance based primarily upon operating income before corporate expenses.

Corporate assets consist primarily of cash but also include plant and equipment associated with our headquarters. These items (and income and expenses related to these items) are not allocated to the segments. Unallocated income/expenses include interest income, interest expense, debt extinguishment and refinancing costs and other (expense) income and certain expenses which are not considered related to either segment, but are instead considered general corporate expenses.

The following table represents sales, operating loss and total assets attributable to these business segments for the periods indicated (in thousands):

	Three Months Ended		Nine Months Ended	
	September	September	September	September
	30,	30,	30,	30,
	2011	2010	2011	2010
Total Sales:				
Medical equipment	\$482	\$ 1,013	\$6,374	\$ 2,414
Radiopharmaceuticals	-	-	-	-
Total Sales	\$482	\$ 1,013	\$6,374	\$ 2,414

Operating loss:

Edgar Filing: POSITRON CORP - Form 10-Q

Medical equipment	\$912	\$ 2511	\$2,946	\$ 12,081
Radiopharmaceuticals	150	-	307	-
Unallocated	38	123	147	799
Total operating loss	\$1,100	\$ 2,634	\$3,400	\$ 12,880

			September 30,	December 31,
			2011	2010
Total assets:				
Medical equipment			\$ 2,906	3,966
Radiopharmaceuticals			26	28
Unallocated			223	1,179
Total assets			\$ 3,155	\$ 5,173

ITEM 2 - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The Company is including the following cautionary statement in this Quarterly Report on Form 10-Q to make applicable and utilize the safe harbor provision of the Private Securities Litigation Reform Act of 1995 regarding any forward-looking statements made by, or on behalf of, the Company. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance and underlying assumptions and other statements, which are other than statements of historical facts. Certain statements contained herein are forward-looking statements and, accordingly, involve risks and uncertainties, which could cause actual results or outcomes to differ materially from those expressed in the forward-looking statements.

The Company's expectations, beliefs and projections are expressed in good faith and are believed by the Company to have a reasonable basis, including without limitations, examination of historical operating trends, data contained in records and other data available from third parties, but there can be no assurance that the Company's expectations, beliefs or projections will result, or be achieved, or be accomplished

Overview

Positron Corporation (the "Company" or "Positron") is a leading molecular imaging company providing innovative nuclear medicine technologies and services that are reshaping the field of nuclear cardiology. Through proprietary PET imaging systems and radiopharmaceutical solutions, Positron enables healthcare providers to more accurately diagnose disease, improve patient outcomes while practicing cost effective medicine. Positron has gained significant traction in a diverse industry and continues their strong commitment to excellence and advancing cardiac imaging solutions.

General

Attrius® PET System

Positron has experienced a significant increase in sales with the introduction of the Attrius® PET imaging system. Positron's Attrius® was developed as a high quality, less expensive, molecular imaging device that will accommodate the growth in molecular imaging and specifically the need by nuclear cardiologists. The Attrius® is the only dedicated PET imaging system on the market. The Attrius® received Food and Drug Administration 510K approval in April 2009 and has been marketed in the U.S. since March 2010. The Company believes that the future of nuclear cardiology is PET and that there is an opportunity for Positron to capture significant market share with an efficient and economical dedicated PET imaging system optimized for cardiac imaging.

Positron's Attrius® provides superior image quality to other more expensive and less efficient imaging systems which presently are only PET/CT systems that are currently offered. A significant advantage to Positron's technology is its proprietary patient management software which improves physician interpretation and patient care, a critical performance component to Positron's Attrius® PET system.

Positron achieved significant advancements on the Company's new state-of-the-art coronary flow reserve (CFR) software, developed in collaboration with the University of Texas. Positron expects to offer this software in conjunction with the Attrius® starting Q2 2012. The CFR software, a clear differentiator and advantage for Positron, was developed by leading cardiologist and industry luminary Dr. K. Lance Gould and is considered to be a key driver in the upcoming growth in cardiac PET.

In addition to technological advantages, Positron's Customer Care Plan - PosiStar™ - provides expert clinical support for physicians, technical support for nuclear technicians, administrative training for practice management and service support that guarantees uptime and top performance of the Attrius®. This customer care provides key support and guidance for the physician and practice as well as the performance of the system. We believe that the growth in the industry and Positron will greatly be enhanced through better customer education, understanding and experience with cardiac PET.

Positron obtained 16 sales contracts for Attrius® systems and installed 5 in 2010, and 8 systems during the nine months ended September 30, 2011. Attrius® systems are sold with PosiStar™, Customer Care Plans.

Sales of PET systems during 2011 have been negatively impacted by shortage of Sr-82/Rb-82 generators supplied to cardiac imaging facilities by Bracco Diagnostics due to the accelerator maintenance and limited production capacity of the isotope Sr-82. In addition, in July 2011, Bracco Diagnostics issued a voluntary recall of its Sr-82/Rb-82 generators for additional testing. In October 2011, Bracco informed its customers that it anticipated a limited and progressive reintroduction of the product to commence in the 1st or 2nd quarter of 2012.

PosiRx™

PosiRx™ is a radiopharmaceutical system that automates the elution, preparation and dispensing processes for radiopharmaceutical agents used in molecular imaging. It was created to simplify and control the procedures associated with compounding radiopharmaceuticals. PosiRx™ integrates features that increase productivity while decreasing exposure and costs. Our system provides molecular imaging departments with 24/7 unit dose accessibility, combined with the reliability of an on-site supply. Additionally, PosiRx™ assists in compliance with all current USP-797 requirements for the production of unit dose radiopharmaceuticals.

Currently cardiac drugs for SPECT imaging agents are prepared at centralized radiopharmacies. Positron's PosiRx™ system enables a "virtual nuclear pharmacy" to be placed into physicians' office, nuclear pharmacies, and hospital cardiology departments providing the ability and ease of use to produce a unit dose automatically with the reliability and control of an "in-house" supply and the necessary tools to comply with USP 797 regulations.

The PosiRx™ was developed as the first system of its kind to offer a complete and comprehensive automated solution for the preparation and dispensing of radiopharmaceuticals.

The PosiRx™ system was introduced in March of 2011 to the American Pharmacist Association Annual Meeting & Exposition and in April 2011 at the American College of Cardiology Annual Conference. The Company has a co-development agreement to develop and custom manufacture automated nuclear pharmacy equipment that functions with Covidien radiopharmaceutical products. The PosiRx™ system has successfully completed testing of key criteria required for validation at the New Mexico Center for Isotopes in Medicine at the University of New Mexico ("UNM"). In addition to the "beta" unit that was tested at UNM, initial, commercial systems have been fully constructed and tested at the Positron facilities in Fisher's Indiana.

Three pilot systems are currently scheduled to be installed with leading nuclear cardiology luminaries and a nuclear pharmacy outside the U.S. To better meet market demand, Positron intends to implement two different revenue models: 1) lease and service PosiRx systems to practices/hospitals handling their own radiopharmaceutical consumables, and 2) sell radiopharmaceutical consumables directly to practices/hospitals through PosiRx systems installed there.

Positron made significant advancements on a proprietary automated quality control module for the PosiRx system, including patent filing for a proprietary method of testing Tc-99m compounds for radiochemical purity. The module is currently in beta prototype testing and is expected to be available by the end of 2011.

RADIOPHARMACEUTICAL MANUFACTURING

Positron has the capacity to manufacture both radioactive and non-radioactive pharmaceutical products and devices at its manufacturing and research and development facility in Crown Point, Indiana. While the Company intends to focus on unique, small batch, radioactive products, the facility also allows for the production of products requiring 510k's, aNDA's, NDA's and IND's, as well as, certified compounding products for pharmacy use. This facility is a research and development foundation for Positron's further expansion into the radiopharmaceutical manufacturing market, a key strategy for the Positron's business objectives.

Positron expects initial revenue from the sale of indium 111In Oxyquinoline (Indium Oxine), an approved generic radiopharmaceutical widely used for the radio-labeling of blood cells. Positron will initially produce and market a radiochemical grade of Indium Oxine and will increase its radiopharmaceutical product offerings as the Company expands into additional markets. Positron filed an amendment to its existing NRC license to allow this site to manufacture and ship radiochemical products to customers. Approval of this amendment is expected in the fourth

quarter of 2011.

Isotopes manufacturing

Positron has been working on execution of a business plan to build and operate a high energy cyclotron facility to be used primarily for production of medical isotopes for diagnostic imaging and radiotherapy. The proposed facility will be equipped with a 70MeV cyclotron and be unique in that it is capable of producing isotopes that are not available or have very limited availability from other commercial sources in the United States. Positron intends to couple a cyclotron with a material processing facility, isotope target manufacturing, drug manufacturing and Positron's expanding equipment-manufacturing operations.

15

The project is planned to be implemented through a wholly owned subsidiary, Positron Isotopes Corporation. Positron executed an agreement with IBA Molecular, of Belgium, to manufacture a 70 MeV cyclotron and contracted American Structurepoint Inc. to design the first facility. The facility will be located in the city of Noblesville, Indiana, concurrent with the relocation of Positron's corporate headquarters and manufacturing.

On July 12, 2011, the Noblesville City Council approved to provide Positron with \$6.7 million in economic incentives through the issuance of long-term Economic Development Tax Increment Revenue Bonds. On September 6, 2011, the Indiana Economic Development Corporation awarded \$38 million of tax-exempt Midwestern Disaster Area Bonds to Positron Corporation.

The major isotope to be produced is Sr-82 that is currently in short supply in the world and produced in the U.S. only by the DOE national laboratories. The isotope is used as a parent isotope for production of Rb-82 in Sr-82/Rb-82 generators for PET myocardial perfusion imaging. This would allow Positron to have a complete integrated value chain that includes radioisotope production, generator distribution, unit dose delivery of the radiopharmaceutical and sale of the PET imaging equipment (Attrius®).

Results of Operations

Comparison of the Results of Operations for the Three Months ended September 30, 2011 and 2010

The Company experienced a net loss of \$1,453,000 for the three months ended September 30, 2011 compared to a net income of \$265,000 for the three months ended September 30, 2010. The decrease in the net income for the current three month period as compared to the same period last year is attributed primarily to the other income recognized during the three months ended September 30, 2010 (the forgiveness of accounts payable and the gain related to the retirement of the derivative liability) which did not occur in 2011.

Revenues - Revenues for the three months ended September 30, 2011 were \$482,000 as compared to \$1,013,000 for the three months ended September 30, 2010. Systems sold during the three months ended September 30, 2011 were \$0 while system sales for the same period in 2010 were \$823,000. The sales of PET scanners have been negatively affected by the shortage of Sr-82 and the recall of Sr/Rb generators by Bracco Diagnostics. Service revenue was \$482,000 and \$190,000 for the three months ended September 30, 2011 and 2010, respectively. The increase in service revenues was largely due to the recognition of \$175,000 of warranty related revenue during the three months ended September 30, 2011, compared to \$0 for the comparable period in 2010.

Gross Margin - Gross margin for the three months ended September 30, 2011 and 2010 was \$(19,000) and \$(113,000), respectively. During the three months ended September 30, 2011, and 2010 the Company recognized \$175,000 and \$0 of revenue related to warranty on the sale of equipment which occurred prior to September 30, 2011.

Operating Expenses - Operating expenses for the three months ended September 30, 2011 were \$1,081,000 compared to \$2,521,000 for the three months ended September 30, 2010.

Research and development costs for the three months ended September 30, 2011 were \$401,000 compared to \$417,000 for the three months ended September 30, 2010. Research and development costs include payroll, contract labor and consulting fees for the development of the PosiRx™, automated radiopharmaceutical system. A portion of the costs include radiopharmaceutical research and development activity at the Company's Crown Point, Indiana facility.

Sales and marketing expense for the three months ended September 30, 2011 and 2010 were \$221,000 and \$343,000, respectively. Sales and marketing expenses for the three months ended September 30, 2011 include salaries and commissions of approximately \$133,000, advertising expense of \$17,000 and trade show expenses of \$41,000. Sales

and marketing expenses for the three months ended September 30, 2010 includes salaries and commissions of approximately \$175,000, advertising expense of \$68,000 and trade show expenses of \$45,000.

General and administrative expenses during the three months ended September 30, 2011 were \$459,000 as compared to \$1,761,000 for the three months ended September 30, 2010. During the three months ended September 30, 2011, these expenses consisted principally of \$123,000 of payroll expense, \$101,000 of consulting expense, and \$95,000 of legal and professional fees. General and administrative expenses during the three months ended September 30, 2010 principally consisted of stock based compensation totaling 1,255,000, \$147,000 of consulting expense, \$175,000 of legal and professional fees and \$116,000 of payroll expense.

Other Income (Expenses) - Interest expense was \$123,000 for the three months ended September 30, 2011 and includes \$108,000 for the accretion of the convertible debentures discount, and \$15,000 for interest payable on the convertible debentures. The Company also recognized derivative losses of \$230,000 on the embedded conversion derivative liabilities during the three months ended September 30, 2011.

During the three months ended September 30, 2010, the Company recorded a \$2,104,000 gain for the retirement of the derivative obligation related to the conversion feature on the convertible debentures which was settled in full and \$824,000 on the forgiveness of accounts payable pursuant to settlements reached with various vendors related to the closed Canadian facility.

Comparison of the Results of Operations for the Nine Months ended September 30, 2011 and 2010

The Company experienced a net loss of \$5,023,000 for the nine months ended September 30, 2011 compared to a net loss of \$9,364,000 for the nine months ended September 30, 2010. The decrease in the current nine month period as compared to the same period last year is attributed primarily to stock based compensation charges during the nine months ended September 30, 2010, partially offset by changes in other income (expense).

Revenues - Revenues for the nine months ended September 30, 2011 were \$6,374,000 as compared to \$2,414,000 for the nine months ended September 30, 2010. PET systems sold during the nine months ended September 30, 2011 were \$5,486,000 compared to \$1,762,000 for the same period in 2010, accounting for the significant increase in revenues.

Gross Margin - Gross margin for the nine months ended September 30, 2011 and 2010 was \$341,000 and \$273,000, respectively. During the nine months ended September 30, 2011 and 2010, the Company deferred \$460,000 and \$297,000, respectfully, of revenue related to warranty on the sale of equipment which will be recognized into revenue over 12 months, which is the warranty term provided for by the Company. In addition, during the nine months ended September 30, 2011 and 2010, the Company recognized \$391,000 and \$51,000, respectfully, of revenue related to warranty on the sale of equipment which occurred prior to September 30. Gross margin for the nine months ended September 30, 2011 was positively impacted from recording a \$250,000 receivable for certain excess freight charges owed from Neusoft.

Operating Expenses - Operating expenses for the nine months ended September 30, 2011 were \$3,741,000 compared to \$13,153,000 for the nine months ended September 30, 2010.

Research and development costs for the nine months ended September 30, 2011 were \$1,062,000 compared to \$881,000 for the nine months ended September 30, 2010. Research and development costs for the nine months ended September 30, 2011 included mostly payroll, contract labor and consulting fees for the development of the PosiRx™, automated radiopharmaceutical system. A portion of the costs include radiopharmaceutical research and development activity at the Company's Crown Point, Indiana facility.

Sales and marketing expense for the nine months ended September 30, 2011 and 2010 were \$888,000 and \$779,000, respectively. Sales and marketing expenses for the nine months ended September 30, 2011 include salaries and commissions of approximately \$446,000, advertising expense of \$110,000 and trade show expenses of \$217,000. Sales and marketing expenses for the nine months ended September 30, 2010 include salaries and commissions of approximately \$387,000, advertising expense of \$128,000 and trade show expenses of \$127,000.

General and administrative expenses during the nine months ended September 30, 2011 were \$1,791,000 as compared to \$11,493,000 for the nine months ended September 30, 2010. The significant decrease is attributable to lower stock based compensation in 2011. During the nine months ended September 30, 2011, general and administrative expense largely consisted of \$449,000 of payroll expenses, \$440,000 of stock compensation, \$237,000 of consulting fees, and \$227,000 of legal and professional fees. During the nine months ended September 30, 2010, the Company granted 2,500,000 Series B Preferred Stock options to employees and recorded stock based compensation expense \$2,500,000 related to the issuance of the options. Additionally, the Company issued preferred and common stock for services and for post-acquisition payment and recorded stock compensation of \$7,125,000 during the nine months ended

September 30, 2010. Also, the Company recorded approximately \$318,000 of payroll expenses and \$282,000 of legal and professional fees during the nine months ended September 30, 2010.

Other Income (Expenses) - Interest expense was \$900,000 for the nine months ended September 30, 2011 and includes the \$700,000 for the accretion of convertible debentures upon conversion to Series B Preferred stock as well as \$173,000 for the accretion of the convertible debentures discount, and \$27,000 for interest payable on the convertible debentures. The Company also recognized derivative losses of \$723,000 on the embedded conversion derivative liability during the nine months ended September 30, 2011.

During the nine months ended September 30, 2010, the Company recorded a \$2,104,000 gain for the retirement of the derivative obligation related to the conversion feature on the convertible debentures and \$1,088,000 on the forgiveness of accounts payable and accrued liabilities pursuant to settlements reached with various vendors related to the closed Canadian facility. Other income also includes \$367,000 of accrued interest forgiven pursuant to a settlement agreement reached with the holder secured convertible notes for which the Company was in default. These notes were satisfied in July 2010.

Liquidity and Capital Resources

At September 30, 2011, the Company had current assets of \$2,838,000 and current liabilities of \$3,683,000 compared to December 31, 2010 when the Company had current assets and current liabilities of \$4,789,000 and \$5,259,000 respectively. Total assets at September 30, 2011 were \$3,155,000 compared to \$5,173,000 at December 31, 2010. Total liabilities were \$5,123,000 and \$5,259,000 at September 30, 2011 and December 31, 2010, respectively.

Cash and cash equivalents at September 30, 2011 were \$194,000 compared to \$1,141,000 at December 31, 2010. Accounts receivable was \$1,215,000 at September 30, 2011 compared to \$514,000 at December 31, 2010.

Current liabilities include accounts payable and accrued expenses of \$1,434,000. Customer deposits of \$1,952,000 include \$1,283,000 of deposits for three Attrius® PET systems, two used machines and approximately \$669,000 from a customer that had placed an order for five Nuclear Pharm-Assist™ systems.

Net cash used in operating activities was \$3,484,000 and \$4,675,000 for the nine months ended September 30, 2011 and 2010, respectively.

Net cash used in investing activities were \$8,000 and \$196,000 for the nine months ended September 30, 2011 and 2010, respectively.

Net cash provided by financing activities was \$2,545,000 and \$5,611,000 for the nine months ended September 30, 2011 and 2010, respectively.

The Company's ability to achieve its objectives is dependent on its ability to sustain and enhance its revenue stream and to continue to raise funds through loans, credit and the private placement of restricted securities until such time as the Company achieves profitability. To date, management has been successful in raising cash on an as-needed basis for the continued operations of the Company. There is no guarantee that management will be able to continue to raise needed cash in this fashion.

The report of the Company's independent public accountants, which accompanied the financial statements for the year ended December 31, 2010, was qualified with respect to the ability of the Company to continue as a going concern. If the Company is unable to obtain debt or equity financing to meet its ongoing cash needs, it may have to limit or disregard portions of its business plans

The Company has no material commitments for capital expenditures at this time. The Company has no "off balance sheet" source of liquidity arrangements.

ITEM 3 – QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not required for smaller reporting companies.

ITEM 4 – CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Based upon an evaluation of the effectiveness of disclosure controls and procedures, our Chief Executive Officer ("CEO") and Chief Financial Officer ("CFO") have concluded that as of the end of the period covered by this Quarterly Report on Form 10-Q our disclosure controls and procedures (as defined in Rules 13a-15(e) or 15d-15(e) under the Exchange Act) were not effective to provide reasonable assurance that information required to be disclosed

in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified by the rules and forms of the SEC and is accumulated and communicated to management, including the CEO and CFO, as appropriate to allow timely decisions regarding required disclosure. As reported in our Annual Report on Form 10-K for the year ended December 31, 2010, the Company's chief executive and financial officer has determined that there are material weaknesses in our disclosure controls and procedures.

The material weaknesses in our disclosure control procedures are as follows:

- 1 Lack of formal policies and procedures necessary to adequately review significant accounting transactions. The Company utilizes a third party independent accounting contractor for the preparation of its financial statements. Although the financial statements and footnotes are reviewed by our management, we do not have a formal policy to review significant accounting transactions and the accounting treatment of such transactions. The third party independent contractor is not involved in the day to day operations of the Company and may not be provided information from management on a timely basis to allow for adequate reporting/consideration of certain transactions.
2. Audit Committee and Financial Expert. The Company does not have a formal audit committee with a financial expert, and thus the Company lacks the board oversight role within the financial reporting process.

During 2011, the Company and its third party consultant, which prepares the financial statements, implemented formal procedures whereby significant accounting transactions and the accounting treatment of such transactions is discussed and documented monthly. The Company anticipates this will allow for the adequate reporting/consideration of complex accounting issues and will remediate the related material weakness.

The Company intends to form an Audit Committee that will establish policies and procedures that will provide the Board of Directors a formal review process that will among other things, assure that management controls and procedures are in place and being maintained consistently. The Company anticipates that this action will remediate the related material weakness.

Changes in Internal Control over Financial Reporting

As reported in our Annual Report on Form 10-K for the year ended December 31, 2010, management is aware that there is a significant deficiency and a material weakness in our internal control over financial reporting and therefore has concluded that the Company's internal controls over financial reporting were not effective as of December 31, 2010. The significant deficiency relates to a lack of segregation of duties due to the small number of employees involvement with general administrative and financial matters. The material weakness relates to a lack of formal policies and procedures necessary to adequately review significant accounting transactions.

During 2011, the Company and its third party consultant, which prepares the financial statements, implemented formal procedures whereby significant accounting transactions and the accounting treatment of such transactions is discussed and documented monthly. The Company anticipates this will allow for the adequate reporting/consideration of complex accounting issues and will remediate the related material weakness.

There have not been any other changes in the Company's internal control over financial reporting during the quarter ended September 30, 2011 that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

PART II OTHER INFORMATION

ITEM 1 – LEGAL PROCEEDINGS

None.

ITEM 2 – UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

During the nine months ended September 30, 2011, investors exercised warrants on preferred stock for which the Company received \$595,000 in cash proceeds and issued 130,000 shares of Series B preferred stock. In addition, the Company received \$250,000 in cash proceeds for warrants and issued 125,000 shares of Series B preferred stock, which were exercised at December 31, 2010, and recorded as receivable from warrants exercise at December 31, 2010.

On July 15, 2011, the Company issued 500,000 shares of common stock to an unrelated party for consulting services.

On August 2, 2011, the Company issued 3,000 shares of Series B stock to an unrelated party for consulting services.

The securities described above were offered and sold in reliance upon exemptions from registration pursuant to Section 4(2) under the Securities Act and Rule 506 of Regulation D promulgated thereunder. The agreements executed in connection with this sale contain representations to support the Registrant's reasonable belief that the Investor had access to information concerning the Registrant's operations and financial condition, the Investor acquired the securities for their own account and not with a view to the distribution thereof in the absence of an effective registration statement or an applicable exemption from registration, and that the Investor are sophisticated within the meaning of Section 4(2) of the Securities Act and are "accredited investors" (as defined by Rule 501 under the Securities Act). In addition, the issuances did not involve any public offering; the Registrant made no solicitation in connection with the sale other than communications with the Investor; the Registrant obtained representations from the Investor regarding their investment intent, experience and sophistication; and the Investor either received or had access to adequate information about the Registrant in order to make an informed investment decision.

ITEM 3 – DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4 – (REMOVED AND RESERVED)

ITEM 5 – OTHER INFORMATION

None.

ITEM 6 – EXHIBITS

Exhibit	Description of the Exhibit
31.1	Chairman of the Board Certification of Periodic Financial Report Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2	Chief Financial Officer Certification of Periodic Financial Report Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1	Chairman of the Board Certification Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2	Chief Financial Officer Certification Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002.
10.1	Interactive Data Files*

This exhibit is furnished herewith, but not deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liability under that section. Such certifications will not be deemed to be incorporated by reference in any filing under the Securities Act or the Exchange Act, except to the extent that we explicitly incorporate them by reference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

POSITRON CORPORATION

Date: November 11, 2011

/s/ Patrick G. Rooney
Patrick G. Rooney
Chief Executive Officer,, Chairman of the Board
(principal executive officer)

Date: November 11, 2011

/s/ Corey N. Conn
Corey N. Conn
Chief Financial Officer
(principal accounting officer)